receptors. Am. J. Physiol. 260 (Endocrinol.
Metab. 23): E183-EBB, 1991.-Cortisol modulates brain functions in humans. This principal endogenous glucocorticoid in humans decreases rapid-eye-movement (REM) sleep and increases slow-wave sleep (SWS). Because cortisol exerts its effect on brain functions via mineralocorticoid receptors (MR) and glucocorticoid receptors (GR), we were interested in which type of corticosteroid receptor mediates these steroid effects on sleep. Healthy men were tested in two double-blind experiments. In experiment I (n = 8), the subject's sleep was tested during four nights: 1) after pretreatment with dexamethasone (Dex, 4 mg/day) for 4 or 6 days and after additional infusion of placebo or cortisol (IO mg/h) during the experimental night, 2) after pretreatment with placebo for 4 or 6 days and after infusion of placebo or cortisol(l0 mg/h) during the experimental night. In experiment II, subjects (n = 10) slept after intravenous administration of potassium canrenoate (200 mg, at 0800 and 1700 h before experimental nights) or placebo. Cortisol infusion moderately increased the percentage of SWS (P < 0.05) and markedly decreased REM sleep (P < 0.01); influence of cortisol on SWS did not depend on pretreatment with Dex. Dex reduced both SWS and REM sleep (P c 0.05). Canrenoate markedly diminished SWS (P c 0.01) but left REM sleep unaffected. The results suggest that corticosteroid-induced changes in SWS are mediated via MR-like central receptors in humans, whereas changes in REM sleep involve GR.
rapid-eye-movement sleep; slow-wave sleep; central mineralocorticoid receptor; central glucocorticoid receptor MINERALOCORTICOID RECEPTORS (MR or type I) and glucocorticoid receptors (GR or type II) have been identified in the rat brain using autoradiographic, immunocytochemical, and in situ hybridization procedures (6, 11, 15, 18, 22) . MR occurs in the rat brain with selective affinity to aldosterone, as is the case in the kidney, and as an MR (localized predominantly in limbic brain), which does not discriminate between aldosterone and corticosterone. The specificity-conferring mechanism determining aldosterone selectivity of MR seems to depend on the enzyme H/3-hydroxysteroid dehydrogenase (lip-OHSD), which converts corticosterone (and cortisol) to their 1 l-oxometabolites with strongly reduced bioactivity (10). The limbic brain contains much less ll@-OHSD than the kidney, and this may explain why neurons in the hippocampus and septum contain the nonselective MR (7, 23). The limbic MR are probably occupied between 80% and 90% or more at all times of intact adrenocortical secretion (5). GR represent the classical glucocorticoid recept,or. These receptors have a lo-fold lower a .ffinity to the major endogenous glucocorticoid in the rat, corticosterone, than the limbic MR (18). GR bind synthetic glucocorticoids such as dexamethasone (Dex) with high affinity. GR are widely distributed in the central nervous system and become occupied in parallel with episodic changes in glucocorticoid concentrations during circadian variations and after stress. Behavioral and neuroendocrine studies suggest that the action exerted via MR on limbic brain function is constitutive and is involved in the control of circadian changes in activity. GR, in contrast, restores disturbances in homeostasis induced by stress (3, 5, 16) . On the neuronal level in hippocampal CA1 neurons, MR maintains neuronal excitability, whereas GR suppresses excitabili ty th at was transiently raised by excitatory stimulation (13 7 14). Accordingly, MR and GR are thought to control behavioral states in a coordinative manner. It is presently unknown whether MR and GR with a similar ligand-binding profile and specific functions as in the rat exist in the human brain.
Previous human studies have demonstrated that sleep processes are sensitive to central corticosteroid actions (1, 2, 8, 9, 12) . Dex as well as cortisol substantially reduced rapid-eye-movement (REM) sleep. Cortisol was found to increase slow-wave sleep (SWS) moderately but significantly, whereas Dex tended to reduce SWS.
The present experiments were aimed to clarify whether different types of corticosteroid receptors mediate changes in SWS and REM sleep, after glucocorticoid administration in humans. Effects shared by Dex and cortisol on REM sleep were hypothesized to be due to GR receptor activation, whereas increases in SWS uniquely observed after cortisol were assumed to involve MR. Experiment I was based on findings of increased hippocampal MR density after subchronic treatment with Dex in rats (20). Accordingly, cortisol-induced increases in SWS were expected to be enhanced after a subchronic pretreatment with Dex, as compared with a placebo pretreatment. Dex treatment per se was expected to reduce SWS (8). In experiment 11, effects of a mineralocorticoid antagonist, potassium canrenoate, were assessed on SWS and REM sleep. Canrenoate was expected to diminish MR-mediated SWS activity, whereas GRrelated changes in REM sleep should not occur.
METHODS
In experiment I, subjects were eight healthy male volunteers (including 1 of the authors) aged between 22 and 32 yr. Ten male students in the same age range participated in experiment II. All men were nonsmokers, and none had a history of sleep disturbances.
Subjects were obliged to get up before 0700 h on the days before experimental nights and not to take any naps during the day. They were acclimated to the experimental sleep conditions by spending one night under conditions of the experiment, including the placements of catheters and the infusion of placebo (saline solution).
The studies were approved by the Committee on Research Involving Human Subjects of the University of Ulm. The experiments took place in an air-conditioned electrically shielded room. Upon arrival at the laboratory, subjects were prepared for polysomnographic recording and blood sampling. Continuous recordings were obtained from 2300 to 0700 h, when the subjects were awakened. For the subject's convenience, in experiment I, he was allowed to turn off the lights whenever he wanted, which was between 2315 and 2415 h. In experiment 11, lights were turned off at 2300 h. In the morning, each subject was asked whether he thought he received an active agent or placebo. In experiment I, subjects were also asked whether or not they believed that they had been treated with an active agent during the pretreatment epoch. In experiment I, each subject was studied on four occasions (in addition to the 1st acclimatization night), i.e., subjects were orally treated with placebo (2 times at 0800 and 2000 h) for a total period of 6 days and were intravenously infused with placebo (Placebo condition; 100 ml saline solution) and cortisol (Cort condition; 10 mg/h, Upjohn, Heppenheim, FRG, diluted in 100 ml saline solution) during the experimental night after the 4th or 6th day of placebo pretreatment.
For the other two experimental occasions, subjects were orally pretreated with Dex (2 mg 2 times/day at 0800 and 2000 h, Merck, Frankfurt, FRG) and were infused with placebo (100 ml saline solution; Dex condition) and cortisol (10 mg/h; Dex + Cort condition) during the experimental nights on days 4 and 6 of pretreatment, respectively. One-half of the subjects were infused with placebo during the night after the 4th day of pretreatment and with cortisol during the night after the 6th day of pretreatment; for the remaining subjects, the order of infusions was reversed. Also, the order of pretreatment conditions was balanced across subjects. Constant rate infusions during experimental nights started at 2300 h and lasted until 0700 h. For each subject, the two pretreatment epochs (with Dex and placebo) were at least 4 wk apart.
In experiment II, subjects were studied on two occasions (in addition to the 1st acclimatization night): in one condition, canrenoate (200 mg aldactone, Hoechst, FRG) was infused intravenously two times within 10 min, at 0800 and 1700 h before the experimental night; i.e., the total dose administered was 400 mg canrenoate.
In the other condition, placebo infusions were administered at 0800 and 1700 h on the day before the experimental night. The two experimental nights of each subject were at least 1 wk apart.
An intravenous forearm catheter (which in experiment I was placed distally to the infusion catheter) was used for blood sampling during experimental nights. This catheter was connected to a long thin tube (vol 1.5 ml), which enabled blood collection from an adjacent room without disturbing the subject's sleep. To prevent clotting -400 ml saline solution were infused throughout the night.
Recordings and data analysis. Sleep stages were determined from recordings of electroencephalogram, electromyogram, and electrooculogram which were scored offline according to the criteria described by Rechtschaffen and Kales (17). Blood samples were taken at 2330, 0100, 0400, and 0700 h to determine plasma concentrations of cortisol. Cortisol was measured by radioimmunoassay (Hermann Biermann, Bad Nauheim, FRG, sensitivity 0.17 ,ug/dl, intra-assay coefficient of variation ~3% between l-50 pg/dl, interassay coefficient of variation <IO%). In experiment II, plasma aldosterone concentrations were also determined by radioimmunoassay in blood samples collected at 2330 and 0700 h (Hermann Biermann, Bad Nauheim, FRG, sensitivity 16 pg/ml, intra-assay and interassay coefficient of variation <lo% between SO-1,000 pg/ml). Samples from an individual subject were analyzed in duplicate in the same assay.
For each night, sleep onset latency (with reference to 2300 h), sleeping time, total time spent in the different sleep stages (awake, sleep stages 1 and 2, SWS, REM sleep), and latencies of the sleep stages (with reference to sleep onset) were calculated. Because SWS consists of both stage 3 and stage 4 sleep, separate analyses were also performed on sleep stages 3 and 4. Results from these analyses will be reported only if they provided additional information going beyond that obtained from analysis of SWS. Percentages of the time spent in the different sleep stages and average plasma cortisol concentrations were calculated for the total sleeping time and, in addition, separately for the first and second half of sleeping time. In experiment I, data were statistically evaluated by analyses of variance, including the repeated measures factors pretreatment (placebo vs. Dex) and nocturnal infusion (placebo vs. cortisol).
Effects of the treatments were post hoc specified by Wilcoxon's t test (one tailed). Statistical evaluation of experiment II was based on Wilcoxon's t test. P < 0.05 was considered significant. Tables 1 and 2 rather than to the absolute amounts of The subchronic administration of Dex (Dex condition) markedly changed nocturnal sleep patterns (Fig. 1 ) compared with the placebo condition. Time spent in REM sleep during Dex was less than one-half of that occurring during placebo nights. The average length of a REM sleep epoch was 22.3 +-2.5 @SE) min during placebo nights and 15.1 t 2.5 min after administration of Dex (P < 0.005). The absolute time as well as the percent of sleep time spent in SWS was significantly reduced after Dex (Fig. Z) , with this effect being accompanied by a significantly (P < 0.02) prolonged latency of the first entry into SWS (Table 1 ). In addition, subjects spent more time awake and in stage 1 sleep during this condition than during placebo nights.
RESULTS
Intravenous infusion of cortisol (Cort condition) also diminished REM sleep (P c 0.01 compared with placebo). However, this reduction was less than that observed during nights after administration of Dex. Unlike Dex, infusion of cortisol increased (P c 0.05) the relative time spent in SWS compared with placebo (for the absolute time spent in SWS the increasing influence of cortisol did not reach statistical significance).
Comparison of the Cort with Dex conditions revealed that during the Cort condition subjects spent on the average substantially more time in SWS (P < 0.01 for the absolute and percent of sleep time in SWS) and almost twice as much time in stage 4 sleep than'during the Dex condition (8.2 t 2.1 vs. 4.5 & 1.7%, PC 0.02). Likewise, the average number of SWS epochs during cortisol infusions exceeded that observed on the nights after Dex (2.9 t 0.4 vs. 1.4 t 0.4, P c 0.01).
When cortisol was infused after subchronic treatment with Dex (Dex + Cort condition), time spent in REM sleep and also the average length of REM sleep epochs (13.1 t 4.1 vs. 22.3 & 2.5 min during placebo, P < 0.02) were reduced almost to the same extent as after Dex alone. In addition, during the Dex + Cort condition REM sleep latencies were also markedly prolonged (Table 1) . The time spent in SWS tended to be longer during the Dex + Cort than Dex condition. However, the effect of cortisol on SWS when infused after administration of Dex did not reach statistical significance. In general, the effects on REM sleep were more clear for the second than first half of sleeping time, whereas hormonal effects on SWS and stage 1 sleep were more consistent during the first half (for statistical results refer to Table 1 ). All subjects recognized when they were treated with Dex. However, they were unable to correctly judge whether cortisol or placebo was infused during the experimental night. not affected after administration of canrenoate. However, aldosterone concentrations at 2330 h were higher after canrenoate (127.1 t 10.2 pg/ml) than placebo (75.3 t 7.1 pg/ml, P < 0.05), with this effect validating the effectiveness of the canrenoate treatment. Plasma aldosterone concentrations at 0700 h did not differ between the placebo (163.1 t 41.5 pg/ml) and canrenoate conditions (160.8 t 19.0 pg/ml). Total sleep time was not different between the placebo and canrenoate conditions. However, canrenoate selectively influenced SWS. Percent of sleep time and absolute time spent in SWS were substantially diminished by the mineralocorticoid antagonist (P < 0.005), and this effect was most pronounced during the first half of sleeping time (Table 2, Figs. 3 and 4) . The average time spent in stage 4 sleep after canrenoate (0.2 t 0.1%) was one-tenth of that during placebo nights (2.0 t 0.5%, P < 0.005). In addition, time awake and in stage 1 sleep after canrenoate was longer than after placebo administration (Table 2) . Also, latency of stage 2 sleep was increased for the canrenoate condition. Canrenoate did not affect REM sleep nor any of the related parameters.
The subjects were unable to correctly identify the treatment they had received before experimental nights.
DISCUSSION
The present experiments have demonstrated significant influences of cortisol, Dex, and of the mineralocor- h between 2300 and 0700 h; Dex, dexamethasone, 2 mg, orally administered 2 times/day for 4 or 6 days; Dex + Cort, administration of 2 mg Dex, 2 times/day for 4 or 6 days and additionai infusion of cortisol, 10 mg/h between 2300 and 0700 h during experimental night). * P < 0.05; * * P < 0.025 compared with effects of placebo condition.
ticoid antagonist canrenoate on sleep processes in humans after systemic administration. REM sleep was substantially reduced after both Dex and cortisol, which is consistent with results reported previously (1, 2, 8, 12) . Because REM sleep remained unchanged after canrenoate, which has very low affinity to GR (DeKloet, unpublished observations), the decrease in REM after both Dex and cortisol may result from activation of GR. The decrease in REM sleep was more pronounced during the conditions with Dex pretreatment (Dex and Dex + Cort) than during the Cort condition. This larger effect of Dex can be attributed to the prolonged treatment and higher dose of the steroid; moreover, affinity to GR is higher for Dex than cortisol (15). SWS was significantly diminished after Dex. In contrast, infusion of cortisol moderately increased the percentage of SWS. However, the effect of cortisol on SWS did not appear to be robust, since the increases in the absolute time spent in SWS and the percentage of SWS during the first half of sleep (when most SWS occurs) did not reach statistical significance. Nevertheless, the increased percentage of SWS after cortisol, in the present study, is in line with results from previous studies indicating that, unlike Dex, cortisol does not reduce SWS but tended to increase it (1, 2, 8). Differential effects on SWS after Dex and cortisol may involve a cortisolinduced activation of MR-like central receptor sites. Given that MR sites are occupied to the greatest extent at all times during intact adrenal release, this would explain also why the increase in SWS during cortisol infusion was only of a small size in the present as well as in the foregoing experiment (1). In view of the extensive occupancy of MR even under basal condition, the administration of an antimineralocorticoid was therefore the method of choice to reveal MR functions in sleep.
The rationale of the combined administration of Dex + Cort was that if Dex indeed increased limbic MR, which it does in animals, this should result in an enhanced response of SWS to cortisol infusion. The data however show that such an effect of cortisol is masked probably by the opposite effect of Dex on SWS. Due to this functional antagonism, the effects of the combined Dex + Cort treatment is at present difficult to interpret.
Unlike Dex and cortisol, the mineralocorticoid antagonist canrenoate did not affect REM sleep. Because this substance has little affinity to GR (DeKloet, unpublished observations), this finding supports the notion that the effects of Dex and Cort on REM sleep are mediated via a GR agonist action. Canrenoate markedly reduced SWS. This effect is not likely to be due to the increase in aldosterone after canrenoate, since, in a previous study (Z), small doses of aldosterone tended to increase rather than decrease SWS. As pointed out previously, differential actions on SWS after cortisol and Dex may involve a selective activation of MR after Cort. Hence, in the light of markedly reduced SWS activity after administration of the MR antagonist canrenoate, it is conceivable that in the human brain changes in SWS are subject to modulation via MR. Most likely, the MR is implicated that does not discriminate between aldosterone and cortisol. These sites prevail in limbic (notably hippocampal) regions and display in vivo and in vitro considerable affinity to canrenone (DeKloet, unpublished observations).
In summary, the present results provide evidence for different mechanisms mediating corticosteroid effects on SWS and REM sleep in men. The findings are consistent with a role of two types of corticosteroid receptors in the human brain in the control of sleep stages, along the criteria that have been used to distinguish the role of MR and GR in the rodent brain. It is hypothesized that effects of cortisol (and synthetic glucocorticoids) on REM sleep are GR mediated, whereas the opposite changes in SWS after the antimineralocorticoid canrensate and the mixed agonist cortisol are mediated via MR.
